{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.05","upperLimit":"6.08","value":"6.08"},{"groupId":"OG001","lowerLimit":"11.5","upperLimit":"32.9","value":"22.23"},{"comment":"NA=Median was not reached (max value was 58.91)","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"NA=Not calculable due to insufficient survival events","groupId":"OG003","lowerLimit":"7.43","upperLimit":"NA","value":"32.92"},{"comment":"NA=Not calculable due to insufficient survival events","groupId":"OG004","lowerLimit":"14.9","upperLimit":"NA","value":"32.49"},{"groupId":"OG005","lowerLimit":"14.0","upperLimit":"35.7","value":"25.00"},{"groupId":"OG006","lowerLimit":"16.6","upperLimit":"43.1","value":"28.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"37"},{"groupId":"OG006","value":"73"}],"units":"Participants"}],"description":"PFS is defined as the time from first dose (phase 1) or time from randomization (phase 2) to disease progression or death. The distribution of PFS was estimated for each treatment group using Kaplan-Meier methodology. Point estimates and 95% CIs for the median for the PFS distribution are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Elotuzumab 5 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG000","title":"Elotuzumab 5 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG001","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG002","title":"Elotuzumab 20 mg/kg + Lenalidomide and Dexamethasone (Phase 1)"},{"description":"Elotuzumab (5, 10, or 20 mg/kg) administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG003","title":"Total (Phase 1)"},{"description":"Elotuzumab 10 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG004","title":"Elotuzumab 10 mg/kg + Lenalidomide and Dexamethasone (Phase 2)"},{"description":"Elotuzumab 20 mg/kg administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG005","title":"Elotuzumab 10 mg/kg Administered as an IV Infusion in Combinat"},{"description":"Elotuzumab (10 or 20 mg/kg) administered as an IV infusion in combination with lenalidomide 25 mg and dexamethasone 40 mg administered orally.","id":"OG006","title":"Total (Phase 2)"}],"paramType":"MEDIAN","populationDescription":"Safety population: All randomized participants who received at least 1 dose of study drug","reportingStatus":"POSTED","timeFrame":"From first dose of elotuzumab (phase 1) or randomization (phase 2) until 60 days following the last infusion (or before initiation of new therapy), up to 101 months","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}